Menu
← Oncology Approval Tracker
FDA DECISION ·
Ensacove
ensartinib · Xcovery Holdings
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with ALK-positive, locally advanced or metastatic non-small cell lung cancer who have not received an ALK inhibitor.
LAMPGEN ANALYSIS
Why it matters
The approval adds an oral ALK inhibitor for ALK inhibitor-naive patients. The pivotal comparison was with crizotinib.
What research teams should watch
Check ALK status and prior drug records, and plan for serial liver tests and prompt review of skin reactions.
PRIMARY RECORDS